Seattle Children's Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Seattle Children's Hospital sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Seattle Children's Hospital: 168 sponsored US clinical trials, 29 recruiting.
Seattle Children's Hospital sponsors 168 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 110 completed. 11 of these trials are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Germ Cell Tumor, with 4 trials.
Top-decile sponsor footprint
Seattle Children's Hospital ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
110 of 117 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 1 of 4
Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products
NCT07424157
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
NCT07148050
I-DECIDE After Bronchiolitis Hospitalization
NCT07243652
Concussion Recovery and Support Program
NCT07097792
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
NCT07281092
Effects of High-Resistance Inspiratory Muscle Strength Training on Cardiorenal and Vascular Function in Youth and Young Adults With Type 2 Diabetes
NCT06936670
Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
NCT06299891
The "What Is Important to Us" Communication Intervention Pilot Clinical Trial
NCT06208332
REACT-01: Reversing Autoimmunity Through Cell Therapy
NCT06465147
Using Ecological Momentary Assessment to Develop an Adaptive Psychological Intervention for Young Adults With Chronic Pain
NCT06932432
Pilot Trial of the RUBI Program for Autistic Adults
NCT06593613
The PRISM-Social Needs (PRISM-SN) Intervention for Adolescents and Young Adults With Cancer
NCT06242964
Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
NCT06315179
Internet-Delivered Pain Self-Management for Persons With Acute Recurrent and Chronic Pancreatitis Pain
NCT06386224
Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
NCT06216899
Concussion Health Improvement Program
NCT06036147
Online Social Learning Program for Parents With Irritable Bowel Syndrome: Raising Resilient Children
NCT05730491
Resilience Mobile App for Teens and Young Adults With Cancer
NCT05842902
Comparing Two Models of Well-Child Care for Black Families
NCT05852392
The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies
NCT06072976
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
NCT05078970
A Comprehensive Trauma-sensitive Approach to Physical Activity Promotion in Schools (CSPAP-T)
NCT05382975
Using Shared Decision Making to Improve Family Media Use Planning
NCT05722535
Brain Injury Education and Outpatient Navigation-1stBIEN
NCT05261477
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
NCT05105152
Laser Photocoagulation of Communicating Vessels in Twin-to-Twin Transfusion Syndrome
NCT05008744
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
NCT04185038
CHronic Nonbacterial Osteomyelitis International Registry
NCT04725422
Fecal Microbiota Transplantation as a Strategy to Eradicate Resistant Organisms
NCT02543866
Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
NCT05768880
Mobile Video Interpretation to Optimize Communication Across Language Barriers
NCT05591586
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
NCT05312411
Intervention for Sleep and Pain in Youth: a Randomized Controlled Trial
NCT04936321
Mobile Subthreshold Exercise Program for Concussion--R01
NCT04688255
Brain Activation and Satiety in Children 2
NCT04520490
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
NCT04571138
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
NCT04483778
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
NCT03618381
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
NCT03684889
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
NCT03500991
A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
NCT03330691
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
NCT03186118
A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma
NCT03244306
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
NCT02311621
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
NCT02028455
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
NCT01683279
Evaluating a Shared Decision-making Intervention for Families About Firearm Storage
NCT07522112
Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
NCT07224568
A Vaccine Communication Training Intervention for Pediatric Inpatient Clinicians
NCT07552857
Bypass Clear Priming VSD Cardiopulmonary Bypass Circuit Reduce Bypass Associated Inflammation?
NCT07393243
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 33 |
| Phase 2 | 7 |
| Phase 3 | 5 |
| Phase 4 | 6 |
Therapeutic Areas
What is open in the Seattle Children's Hospital pipeline
29 recruiting of 168 indexed (17% open); 110 completed (65%).
Phase mix: 11 late (III/IV) vs 40 early (I/II) (early-phase heavy).
Top condition: Germ Cell Tumor (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Seattle Children's Hospital: open-pipeline peers nationwide
Peers matched on 168 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Seattle Children's Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Bausch Health Americas · 168 trials · 4% recruiting
- Sumitomo Pharma America · 168 trials · 4% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Johns Hopkins University · 17% recruiting · 1,448 trials
- Hunter College of City University of New York · 17% recruiting · 29 trials
- Ochsner Health System · 17% recruiting · 29 trials
- Baylor Research Institute · 17% recruiting · 180 trials
Related
What to do with this Seattle Children's Hospital page
168 registered trials is a research-attention snapshot, not an endorsement of Seattle Children's Hospital or any single study.
- 29 of Seattle Children's Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Germ Cell Tumor is the condition Seattle Children's Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Germ Cell Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Seattle Children's Hospital pipeline card: 168 registered trials from official public datasets.Report a data error.